Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-371-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.42 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health Inc (NASDAQ:JAGX) released its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.10. The biotechnology company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.10 million. Jaguar Health had a negative return on equity of 261.14% and a negative net margin of 726.80%. View Jaguar Health's Earnings History.
When is Jaguar Health's next earnings date?
What is the consensus analysts' recommendation for Jaguar Health?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.
Has Jaguar Health been receiving favorable news coverage?
Media coverage about JAGX stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jaguar Health earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting Jaguar Health?
Jaguar Health saw a decrease in short interest in March. As of March 29th, there was short interest totalling 309,546 shares, a decrease of 56.2% from the March 15th total of 707,275 shares. Based on an average daily trading volume, of 26,815,240 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.8% of the shares of the company are short sold. View Jaguar Health's Current Options Chain.
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include OASMIA PHARMACE/ADR (OASM), Catabasis Pharmaceuticals (CATB), Sesen Bio (SESN), Fortress Biotech (FBIO), Adamis Pharmaceuticals (ADMP), Cumberland Pharmaceuticals (CPIX), Nemus Bioscience (NMUS), Infinity Pharmaceuticals (INFI), Tiziana Life Sciences (TLSA), VERONA PHARMA P/S (VRNA), SCYNEXIS (SCYX), Apricus Biosciences (APRI), Merrimack Pharmaceuticals (MACK), Otonomy (OTIC) and Eyenovia (EYEN).
What other stocks do shareholders of Jaguar Health own?
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
- Ms. Karen S. Wright, CFO & Treasurer (Age 63)
- Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
- Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
- Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel
When did Jaguar Health IPO?
(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $0.23.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $22.94 million and generates $4.42 million in revenue each year.
What is Jaguar Health's official website?
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
